Marcin et al. reported that TMB levels in 567 NSCLC patients was significantly correlated with anti-PD-L1/PD-1 efficacy in a clinical trial(Kowanetz et al. 2017). The gene discussed is CD274; the disease is non-small cell lung carcinoma.